Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.
Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.
Abstract: A functionalized nanomaterial, such as a nanoparticle, can include a polythioaminal functionalized surface. The polythioaminal linked to the surface of the nanomaterial can be bonded to a compound such as therapeutic and/or diagnostic materials. The thiol-based linkages can be used to bond the polythioaminal to both the nanomaterial and the therapeutic and/or diagnostic materials. Polythioaminals can be prepared via reactions of triazine and dithiols. Polythioaminals thus prepared can be further modified to provide linkages to the nanomaterial and other compounds such as medicinal compound, peptides, and dyes. Nanomaterials including such compounds linked thereto via the polythioaminal can be supplied for therapeutic and/or diagnostic purposes to biological target regions.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
November 26, 2019
Assignee:
International Business Machines Corporation
Inventors:
Dylan J. Boday, Jeannette M. Garcia, James L. Hedrick, Rudy J. Wojtecki
Abstract: The invention relates to a method for inhibiting an ADAM protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the ADAM protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an ADAM protease, as well as associated pharmaceutical compositions, uses and methods of treatment.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
November 12, 2019
Assignees:
CANCER RESEARCH TECHNOLOGY LIMITED, KING'S COLLEGE LONDON
Abstract: Disclosed are a composition including (6S)-5-methyl tetrahydrofolic acid or a salt thereof, and preparation and use thereof. In the composition, the content of (6S)-5-methyl tetrahydrofolic acid or the salt thereof is not less than 98.0%, the content of a related impurity JK12A is not greater than 0.1%, and 5-methyl tetrahydropterioic acid is not detectable.
Abstract: A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60 wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.
Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Type:
Grant
Filed:
February 14, 2018
Date of Patent:
July 23, 2019
Assignee:
Heron Therapeutics, Inc.
Inventors:
Steven Y. Ng, Hui-Rong Shen, Jorge Heller
Abstract: Cosmetic agents and methods for temporarily shaping keratin-containing fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent includes a cosmetic carrier. The cosmetic agent further includes at least one chitosan or derivative thereof. The cosmetic agent further includes at least one hydrophobic pyrogenic silicic acid. The cosmetic agent also includes at least one non-ionic, anionic, or amphoteric film-forming polymer. In another embodiment, the method includes the step of using the cosmetic agent for temporarily shaping keratin-containing fibers.
Abstract: The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: wherein the definitions of T, Q, R1 and R2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.
Abstract: The present invention relates to a cosmetic composition, in which a high-content of oil-soluble components is stabilized using a natural surfactant, and more specifically to a cosmetic composition, in which by using a plant-derived natural surfactant and a high-pressure emulsification method without using PEG-based or ionic surfactants that may cause skin irritation, a transparent gel formulation containing a high-content of oil-soluble components can be realized, thereby effectively combining the advantage of an oil formulation excellent in moisturizing power, and the advantages of a moisture gel formulation, which is easy to use without flowing down, and has a fresh feeling of use.
Type:
Grant
Filed:
September 7, 2015
Date of Patent:
July 9, 2019
Assignee:
AMOREPACIFIC CORPORATION
Inventors:
Byung Ryol Paik, Byung Young Kang, Soon Ae An, Joon Young Hwang, Wha Young Shin
Abstract: The present invention relates to cosmetic compositions obtained or obtainable from Salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for reducing or preventing the cosmetic appearance or prevalence of wrinkles, fine lines, hyperpigmentation, laxity, dry skin, scaling and/or transepidermal water loss in skin of a mammalian animal.
Type:
Grant
Filed:
June 25, 2012
Date of Patent:
June 25, 2019
Assignee:
AQUA BIO TECHNOLOGY ASA
Inventors:
Bernt T H. Walther, Hans Kristian Leren
Abstract: The invention relates to novel compositions and methods for diagnosing or treating food allergies. The invention particularly discloses new approaches for delivering food allergens to allergic patients by oral administration of formulations which dissolve and release proteins in the stomach. The invention allows the treatment of food allergies by delivering food allergens to the gut immune system with controlled exposure of the esophagus or oral cavity. The invention also allows to perform food challenges to assess the threshold of clinical reactivity without exposing the esophagus and oral cavity. The invention may be used in any subject, particularly human subjects, and is applicable to any food allergen.
Abstract: Short tri- and tetrapeptides according to the following Formula I Ar(CH2)mX1—X2—CO—X3—X4—X5-(Trp)n-NX6R are potent, selective agonists of melanocortin 1 receptor (MC1R). Provided herein are pharmaceutical compositions including Formula I peptide agonists of MC1R and methods of treating skin diseases and disorders that include administering to an individual in need thereof a therapeutic amount of a Formula I peptide. The peptides, pharmaceutical compositions, and methods described herein are useful in the treatment of diseases and disorders that benefit from agonism of MC1R, including melanoma, basal cell carcinoma, squamous cell carcinoma, porphyria, polymorphous light eruption, vitiligo, and solar urticaria.
Type:
Grant
Filed:
October 26, 2017
Date of Patent:
May 28, 2019
Assignee:
University of Cincinnati
Inventors:
Zalfa A. Abdel-Malek, Leonid Koikov, James J. Knittel
Abstract: Microfibrous cellulose (MFC) broths are provided having improved performance as compared to wet cake microfibrous cellulose (MFC) and powdered microfibrous cellulose (MFC). In embodiments, compositions having an effective amount of an MFC broth and an effective amount of a surfactant have an improved yield value as compared to a composition having a surfactant and a wet cake MFC, a powdered MFC, or a combination thereof at the same concentration as the MFC broth. Also, methods are provided for improving the yield value of surfactant compositions by adding an effective amount of a microfibrous cellulose broth to an effective amount of surfactant to provide a surfactant composition having a yield value that is higher than a composition having the surfactant and a wet cake MFC, a powdered MFC, or a combination thereof at the same concentration as the microfibrous cellulose broth.
Type:
Grant
Filed:
April 12, 2013
Date of Patent:
May 21, 2019
Assignee:
CP Kelco U.S., Inc.
Inventors:
John Swazey, Neil Morrison, Zhi-fa Yang, Jacqueline Compton, Tim Nolan
Abstract: Disclosed are a hyaluronic acid-based amphiphilic polymer, preparation method and application thereof. A main chain of the amphiphilic polymer is a hydrophilic hyaluronic acid and can be employed in active targeting, and a side chain thereof is a hydrophobic group represented by Formula (1). The amphiphilic polymer can carry a small molecule anticancer drug. Polymer nanoparticles are obtained via chemical crosslinking, such that the nanoparticles are not readily dissociated outside a cell or in blood, thus ensuring the stability of a drug encapsulated by the nanoparticles. Upon arriving at a tumor tissue, the hyaluronic acid on a surface of the nanoparticle can immediately combine with a CD44 receptor on a surface of a tumor cell, and effectively enter the tumor cell via endocytosis mediated by the receptor, and then quickly de-crosslink to be dissociated.
Abstract: The present invention provides a peptide consisting of an amino acid sequence of SEQ ID NO: 1. Also provided is a method for promoting proliferation of a dermal papilla cell by incubating the cell with the peptide. Further provided is a method for promoting growth of a hair follicle in a skin by applying the peptide to the skin. Still provided is a method for preventing hair loss of a subject by administering the peptide to the subject. Yet further provided is a method for promoting hair growth of a subject by administering the peptide to the subject.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
May 7, 2019
Assignee:
H&H GROUP CO., LTD.
Inventors:
Min-Chuan Huang, Hsiao-Yu Chen, Syue-Ting Chen, He Xu, Pun Tsui
Abstract: The present invention relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, talc and one UV sunscreen ingredient. It also relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, at least 1% by weight of at least one mineral filler relative to its total weight, and one UV sunscreen ingredient.
Abstract: Some embodiments are directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein determining the level of octameric PTX3 includes measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 present, and calculating the proportion of total PTX3 which is present as octamer, wherein if the proportion of octameric PTX3 is greater than 50%, the subject is identified as a likely non-survivor. Some embodiments are also directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein an elevated level of octameric PTX3 compared to a reference level indicates a reduced likelihood of survival.
Abstract: The present invention is directed toward an article of apparel configured to deliver a bioabsorbable alloy to the skin of a wearer. In an embodiment, the apparel is a textile base layer and a delivery layer oriented to contact the skin of the wearer. The delivery layer is formed from a composition including a magnesium alloy. In another embodiment, the textile is formed of strands coated with the magnesium alloy composition. In still further embodiments, the strands are formed of the alloy. The apparel may be configured to release a therapeutically effective amount to the user.
Abstract: In some aspects of the present invention is a formulation comprising a solid dispersion or intimate mixture of a poorly water soluble drug and an ionic polymer surprisingly exhibiting fast disintegration of tablet.
Type:
Grant
Filed:
December 19, 2013
Date of Patent:
February 5, 2019
Assignee:
Kashiv Pharma, LLC
Inventors:
Jelena Djordjevic, Murali Mohan Bommana, Wantanee Phuapradit, Navnit H. Shah, Christopher A. Pizzo